ON SEMICONDUCTOR CORP (ON) Stock News

Rosen Law Firm is reminding investors who purchased Datavault AI Inc. securities between September 4, 2024 and October 30, 2025 of an important October 5, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that defendants made materially false statements regarding corporate partnerships, overstated trading activity on the Datavault Platform, and failed to disclose connections with a convicted felon, causing reputational harm.

Ferrari N.V. has completed its €250 million second tranche of share buybacks, purchasing 815,739 common shares across Euronext Milan and NYSE for €249.999 million. The company announced a third tranche of up to €250 million starting September 2, 2026, to be executed through non-discretionary agreements with primary financial institutions. Since January 2026, Ferrari has repurchased 1,701,184 shares totaling €510.76 million as part of its €3.5 billion multi-year buyback program expected to conclude by 2030.

While On Holding (ONON) has a strong buy-equivalent average brokerage recommendation (ABR) of 1.52 from 25 firms, the article cautions that brokerage recommendations are often biased due to institutional conflicts of interest. The Zacks Rank, a quantitative model based on earnings estimate revisions, provides a more reliable indicator. On Holding's consensus earnings estimate has declined 2.1% over the past month, resulting in a Zacks Rank #5 (Strong Sell) rating, suggesting investors should be skeptical of the positive brokerage consensus.

WisdomTree U.S. MidCap Dividend ETF (DON) is reviewed as a solid mid-cap value investment option with $4.02 billion in assets and a 0.38% expense ratio. The ETF has returned 12.73% year-to-date and 11.32% over the past year, with a medium risk profile. However, it carries a Zacks ETF Rank of 3 (Hold), and competitors like Vanguard Morningstar Mid-Cap Value ETF offer lower expense ratios.

Rosen Law Firm is reminding investors in Bloom Energy Corporation, Wise Group plc, and DNOW Inc. of upcoming deadlines to join securities class action lawsuits. The primary case involves Bloom Energy, which allegedly made false statements about its supply chain by failing to disclose that scandium was sourced from China through intermediaries, misleading investors about the company's business operations and prospects.

Rosen Law Firm is reminding investors who purchased HDFC Bank Limited (NYSE: HDB) securities between July 17, 2023 and May 26, 2026 of an October 13, 2026 deadline to join a class action lawsuit. The lawsuit alleges that HDFC Bank made materially false statements by camouflaging payments as marketing spend to pay higher interest to a state firm, activities allegedly approved by senior management that likely violated regulations and overstated interest income and operating expenses.

A securities class action lawsuit has been filed against UWM Holdings Corporation for allegedly making materially false statements regarding its hedging strategy for mortgage servicing rights. Investors who purchased UWMC securities between March 9, 2026 and August 5, 2026 may be entitled to compensation. The deadline to serve as lead plaintiff is October 13, 2026.

Rosen Law Firm is reminding investors in Aardvark Therapeutics, Inc. of an October 13, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aardvark made materially false and misleading statements regarding the safety and prospects of its drug ARD-101, and failed to disclose material adverse facts about the company's business and operations.

BNP Paribas has issued a statement regarding ongoing Sudan litigation, asserting that the trial court misinterpreted Swiss law and committed legal errors. The bank claims its financial transactions were authorized under Swiss and European law, and states it has support from the Swiss and US governments, academics, and professional organizations. BNP Paribas expressed confidence in presenting its case before the appellate court.

BNP Paribas has filed an appeal in Sudan litigation, asserting that the trial court misinterpreted Swiss law and committed legal errors. The bank claims its financial transactions were authorized under Swiss and European law, and states it has support from the Swiss government, US government, academics, and industry organizations in its position.

A securities class action lawsuit has been filed against Capricor Therapeutics for allegedly making materially false statements regarding its Deramiocel cell therapy. The lawsuit claims the company made undisclosed changes to statistical analysis plans for clinical data and failed to obtain FDA agreement before resubmitting the Biologics License Application, creating substantial regulatory approval risks. Investors who purchased securities between December 17, 2025 and July 26, 2026 may be eligible for compensation, with a lead plaintiff deadline of September 28, 2026.

Rosen Law Firm has filed class action lawsuits against Hyliion Holdings Corp. (HYLN) for alleged false statements regarding a business deal with a recently formed entity lacking actual operations, and potential insider trading by executives. A separate class action has been filed against Insulet Corporation (PODD) with an August 31, 2026 deadline for lead plaintiff motions. Both lawsuits allege material misstatements that caused investor losses.

Rosen Law Firm reminds investors of Insulet Corporation who purchased securities between February 21, 2025 and May 26, 2026 of the August 31, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Insulet made false statements regarding defective manufacturing controls and procedures that created safety risks, resulting in investor damages.

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. Disc Medicine's stock price fell 22% on the news. Investors who purchased Disc Medicine securities may be eligible to join a class action lawsuit seeking recovery of losses.

A securities class action lawsuit has been filed against EquipmentShare.com Inc (NASDAQ: EQPT) alleging that defendants made materially false and misleading statements regarding undisclosed related party transactions and failed to disclose material adverse facts about the company's business and financial statements. Investors who purchased EQPT securities during the IPO in January 2026 or between January 23 and June 23, 2026, may be eligible for compensation. The lead plaintiff deadline is September 21, 2026.

Honeywell International Inc. (HON) declined 1.34% on August 28, 2026, underperforming the S&P 500. The stock has lost 8.9% over the past month and faces significant headwinds with expected EPS down 61.88% and revenue down 51.13% for the upcoming quarter. The company holds a Zacks Rank of #5 (Strong Sell) with a Forward P/E ratio of 26.71, well above its industry average of 13.01.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing false and misleading statements regarding insurance coverage timelines for its epinephrine nasal spray product 'neffy' with CVS Caremark. Investors who purchased securities between March 9, 2026 and June 24, 2026 may be eligible for compensation. The lead plaintiff deadline is October 5, 2026.

Rosen Law Firm has filed a class action lawsuit against Taboola.com Ltd. (NASDAQ: TBLA) on behalf of investors who purchased securities between May 6, 2026 and August 4, 2026. The lawsuit alleges that Taboola.com made materially false and misleading statements regarding its business operations, specifically failing to disclose an increase in low-quality publishers and the need for aggressive exit strategies that would impact earnings. Investors who wish to serve as lead plaintiff must file by October 20, 2026.

Rosen Law Firm announced multiple securities class action lawsuits with upcoming deadlines. The primary case involves Wix.com Ltd., where investors who purchased securities between February 19, 2025 and May 12, 2026 may be eligible for compensation. The lawsuit alleges Wix made false statements about its AI product offerings, overstating competitiveness and performance while understating development costs. The lead plaintiff deadline is September 22, 2026. Similar class actions were also filed against Microvast Holdings, Inc. and Photronics, Inc.

A class action lawsuit has been filed against Pentair plc for allegedly failing to disclose significant inventory destocking in its Pool channel between April 28, 2026 and July 14, 2026, which adversely affected sales and operating income. The company's positive statements about its business and prospects are alleged to be materially misleading. Investors who purchased Pentair securities during the class period have until October 2, 2026 to apply for lead plaintiff status.

Expion Energy (XPON) was upgraded from Underperform to Neutral, reflecting new growth opportunities in oil and gas exploration and expanded Forest River battery relationships. However, the company faces headwinds including declining battery sales (down 28.6% YoY), recurring losses, high customer concentration, and liquidity concerns. The company plans to drill an exploratory well in Eastern Louisiana by February 2027 and launch next-generation lithium-ion battery models in H2 2026.

Onco360, the nation's leading independent specialty pharmacy, has been selected as a pharmacy partner by Revolution Medicines for the launch of RASONQUE (daraxonrasib), a RAS GTPase inhibitor for metastatic pancreatic adenocarcinoma. The drug showed significant clinical benefits in the phase 3 RASolute-302 trial, with median PFS of 7.3 months and OS of 13.2 months in RAS G12 mutation patients compared to 3.5 months and 6.6 months respectively for chemotherapy.

A securities class action lawsuit has been filed against Pentair plc for allegedly making materially false and misleading statements regarding its business operations. The lawsuit claims defendants failed to disclose significant inventory destocking in the Pool channel that adversely affected sales and operating income. Investors who purchased Pentair securities between April 28, 2026 and July 14, 2026 may be eligible for compensation, with a lead plaintiff deadline of October 2, 2026.

New America Acquisition I Corp. (NYSE: NWAX) announced leadership changes on August 26, 2026, with George O'Leary resigning as CFO and Tim S. Ledwick appointed as the new CFO and Christopher Devall as COO. Both new executives bring extensive experience in financial leadership and operations. The company continues its search for a business combination focused on American industrial strength and innovation.

Glancy Prongay Wolke & Rotter LLP is investigating Sionna Therapeutics for potential securities law violations following the company's announcement of a primary endpoint miss in its PreciSION CF Phase 2a trial on August 10, 2026. The news triggered a 91.2% stock price decline, falling from approximately $46.64 to $4.10 per share, prompting a class action lawsuit on behalf of affected shareholders.

Rosen Law Firm is urging investors who purchased Blaize Holdings securities between July 18, 2025 and April 28, 2026 to join a securities class action lawsuit. The lawsuit alleges that Blaize made false statements about business transactions, improperly recognized revenue, and misled investors about its growth. The lead plaintiff deadline is October 5, 2026.

The FDA has approved RASONQUE (daraxonrasib), developed by Revolution Medicines, as the first targeted RAS inhibitor for treating metastatic pancreatic adenocarcinoma in patients who have received prior systemic therapy or are not candidates for multiagent chemotherapy. In the Phase 3 RASolute 302 trial, RASONQUE reduced the risk of death by 60% compared to chemotherapy, with median overall survival of 13.2 months versus 6.7 months, and demonstrated manageable safety with improved quality of life measures.

The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. Disc Medicine's stock price fell 22% on the news. Investors who suffered losses are encouraged to join a prospective class action.

Rosen Law Firm is reminding investors who purchased ARS Pharmaceuticals securities between March 9, 2026 and June 24, 2026 of an October 5, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals provided false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product (neffy) through CVS Caremark, causing investors to purchase securities at artificially inflated prices.

A securities class action lawsuit has been filed against Pentwater Capital Management LP and its CEO Matthew Halbower, alleging they orchestrated a market manipulation scheme involving Avis Budget Group stock. The defendants, holding approximately 51% economic interest in Avis, allegedly engaged in aggressive stock purchases during February 2025 to April 2026 that triggered a short squeeze, artificially inflating the stock price and benefiting their holdings. Investors who purchased Avis securities during this period may be eligible for compensation, with a September 29, 2026 deadline to serve as lead plaintiff.